Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 7Neoplasms by Histologic Type 3Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Neuroendocrine Tumors 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lymphatic Diseases 2Immune System Diseases 2Digestive System Neoplasms 2AIDS-Related Complex 2Urogenital Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Recurrence 1Prostatic Diseases 1Prostate Cancer Metastatic 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Pancreatic Diseases 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1

Interventions

3-Iodobenzylguanidine 8lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 5Temozolomide 4Specimen Handling 4Magnetic Resonance Spectroscopy 4anlotinib 3Everolimus 3olaparib 2cabozantinib 2belzutifan 2Sunitinib 2Phenoxybenzamine 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1talazoparib 1spartalizumab 1pembrolizumab 1pazopanib 1lanreotide 1guadecitabine 1fluorodopa F 18 1fludarabine phosphate 1copper dotatate CU-64 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × Lutetium × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡